CEL-SCI Co. (NYSE:CVM) Sees Large Decline in Short Interest

Key Points

• CEL-SCI Co. (NYSE:CVM) experienced a significant 50.6% decrease in short interest in July, with total short interest falling from 1,540,000 shares to 760,700 shares.
• CEO Geert R. Kersten increased his position by 66.91%, purchasing 29,197 shares at $6.85 each, bringing his total ownership to 72,835 shares.
• Bank of America Corp DE significantly boosted its investment in CEL-SCI by 2,188.2% during the second quarter, acquiring 39,190 additional shares.

CEL-SCI Co. (NYSE:CVM - Get Free Report) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totaling 760,700 shares, adecreaseof50.6% from the July 15th total of 1,540,000 shares. Based on an average daily trading volume, of 815,300 shares, the days-to-cover ratio is presently 0.9 days. Approximately11.3% of the company's shares are short sold. Approximately11.3% of the company's shares are short sold. Based on an average daily trading volume, of 815,300 shares, the days-to-cover ratio is presently 0.9 days.

Insider Buying and Selling at CEL-SCI

In other news, CEO Geert R. Kersten acquired 29,197 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was bought at an average cost of $6.85 per share, for a total transaction of $199,999.45. Following the completion of the transaction, the chief executive officer directly owned 72,835 shares in the company, valued at $498,919.75. This represents a 66.91% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 9.93% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

An institutional investor recently raised its position in CEL-SCI stock. Bank of America Corp DE grew its holdings in shares of CEL-SCI Co. (NYSE:CVM - Free Report) by 2,188.2% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 40,981 shares of the company's stock after buying an additional 39,190 shares during the quarter. Bank of America Corp DE owned 0.60% of CEL-SCI worth $94,000 at the end of the most recent reporting period. 12.08% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Wall Street Zen assumed coverage on shares of CEL-SCI in a report on Friday, May 16th. They issued a "sell" rating for the company.

CEL-SCI Stock Up 6.9%

Shares of NYSE CVM opened at $8.70 on Friday. The stock has a market capitalization of $59.87 million, a P/E ratio of -18.12 and a beta of 0.52. The company has a 50-day moving average price of $4.76 and a 200-day moving average price of $6.87. CEL-SCI has a 1 year low of $1.98 and a 1 year high of $39.30. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.07 and a quick ratio of 1.09.

CEL-SCI Company Profile

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.